TCT 2019 | AUGUSTUS ACS: Apixaban vs. Warfarin and Aspirin vs. Placebo in AF and ACS

Courtesy of SBHCI.

The safety and efficacy of antithrombotic and antiplatelet treatments in patients with atrial fibrillation admitted with acute coronary syndrome (who receive medical treatment or angioplasty) may vary from that in patients undergoing elective treatment.

Highlights TCT 2019

At 14 days from elective angioplasty or hospitalization due to acute coronary syndrome, patients were randomized in a 2×2 factorial trial to apixaban vs. warfarin and aspirin vs. placebo; additionally, they all received a P2Y12 inhibitor for the first 6 months. Patients admitted due to acute coronary syndrome received angioplasty or medical treatment at the discretion of the treating physician.

Patients randomized to apixaban received 5 mg every/12 h unless they met two of the three risk criteria (age >80 years, weight <60 kg or creatinine 1.5 mg/dL); in that case, the dose was 2.5 mg every/12 h. Patients randomized to warfarin had a target INR between 2 and 3. Both anticoagulant and antiplatelet therapies were started within 24 h from the randomization, and their duration was 6 months.


Read also: TCT 2019 | IDEAL-LM: Bioabsorbable Polymer DES vs. Permanent Polymer DES for Left Main Stenosis.


Events were analyzed according to three possible scenarios: clinically-treated acute coronary syndrome, angioplasty-treated acute coronary syndrome, and elective angioplasty.

Of the 4614 patients included, about 1097 (23.9%) were admitted due to acute coronary syndrome and underwent medical treatment, 1714 (37.3%) were admitted due to acute coronary syndrome and underwent angioplasty, and 1784 (38.8%) underwent elective angioplasty.

Compared with warfarin, apixaban reduced the number of major bleeding events in all clinical scenarios, with the same rate of ischemic events.

Aspirin patients had higher rates of bleeding in all clinical scenarios, with the same rate of ischemic events as placebo patients.

Conclusion

An antithrombotic regime with apixaban plus a P2Y12 inhibitor without aspirin was safer and just as effective in patients with atrial fibrillation admitted with acute coronary syndrome receiving medical treatment or angioplasty when compared with patients who undergo elective angioplasty.

Courtesy of SBHCI.

Link to the SBHCI publication HERE

augustus-stephan

Original Title: AUGUSTUS ACS: A 2×2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome.

Author of the Original Title: Stephan Windecker.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which reflects in lower rates of target lesion...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral anticoagulant (OAC) therapy. This creates a complex...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....